Meet us at TIDES Europe 2026
3-5 November 2026, Amsterdam, Netherlands
Learn more and schedule a meetingPress release
Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share
Read moreCreating the future in peptides
We lead innovation in peptide API’s to the benefit of millions of patients
Contact usMarket leader in peptide API manufacturing and services
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) supporting pharmaceutical and biotech companies in the development and manufacturing of proprietary and generic active pharmaceutical ingredients (API).
Definitive end result of the public tender offer of Samsung Biologics Co., Ltd.
5 Nov 2026 - Baar, Switzerland, 5 November 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the definitive end […]
Read moreProvisional end result of the public tender offer of Samsung Biologics Co., Ltd.
2 Nov 2026 - Baar, Switzerland, 2 November 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the provisional end […]
Read more